Neptune Wellness Solutions Inc.

Consolidated net revenue for Q2 fiscal 2024 was $8.7 million, down from $12.0 million in Q2 fiscal 2023. Consolidated gross loss was $0.6 million versus gross profit of $1.1 million a year ago. Consolidated SG&A expenses were $3.8 million, down from $15.9 million year over year. Consolidated adjusted EBITDA loss was $3.2 million, compared with $13.7 million in the prior-year quarter. Management did not provide next-quarter or full-year revenue/EPS guidance on the call. Instead, it highlighted expected full savings from Sprout cost actions in Q3, ongoing cost cutting at Biodroga, and continued review of capital options and strategic transactions.

Michael Cammarata framed the quarter as part of a broader strategic evolution rather than a standalone operating story. He emphasized the proposed Sprout spin-out, saying it is meant to make each business more focused and agile, lower Neptune’s debt exposure, and let Sprout pursue growth and acquisitions more independently. He also said Biodroga is becoming a more scalable B2B platform, with international expansion and private-label opportunities, and described the company as trying to optimize costs while re-accelerating growth.

Lisa Gainsborg said the quarter reflected lower revenue and a gross loss, but also substantial cost reduction and balance-sheet actions. She cited consolidated SG&A of $3.8 million, down $12.1 million year over year, and noted that the debt exchange increased Neptune’s Sprout ownership to approximately 89.5% while removing Neptune as guarantor for Sprout promissory notes, subject to consent. She also said Neptune prepaid in full its senior secured notes after paying about $2.3 million, with the notes carrying a 16.5% fixed interest rate, and that the company raised $4.5 million in a public offering during the quarter.

Analyst Aaron Grey asked how management was thinking about the overall strategy with a separate Sprout public company, Biodroga, and potential acquisitions. Cammarata said the goal is to unlock growth by making each business more focused, with Sprout positioned to grow brands and Biodroga aimed at bigger global customers and retailer private-label opportunities. Grey also asked why Sprout revenue dipped sequentially despite strong distribution gains; management said the main issue was a shift in SKU mix, out-of-stocks, and co-manufacturing problems, and that production is being adjusted to match demand and add redundancy.